A Clinical Trial to Evaluate the Effect of Neoadjuvant MK-3475 (Pembrolizumab) Therapy on Intratumoral Immune Infiltrates in Renal Cell Cancer (RCC) Patients Undergoing Surgical Resection
Phase of Trial: Phase I
Latest Information Update: 20 Sep 2017
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Merck Sharp & Dohme
- 15 Sep 2017 Planned End Date changed from 20 Jun 2021 to 21 Jun 2021.
- 15 Sep 2017 Planned primary completion date changed from 1 Oct 2019 to 21 Jun 2021.
- 10 Jun 2017 Biomarkers information updated